ইঙ্গিত
Droniva is indicated for the: Treatment of osteoporosis in women (specially postmenopausal) Prevention of osteoporosis in women (specially postmenopausal) Prevention and treatment of osteoporosis in men Treatment of Osteoporosis: Osteoporosis ... Read moreDroniva is indicated for the: Treatment of osteoporosis in women (specially postmenopausal) Prevention of osteoporosis in women (specially postmenopausal) Prevention and treatment of osteoporosis in men Treatment of Osteoporosis: Osteoporosis may be confirmed by the finding of low bone mass (T-score <-2.0 SD) and the presence or history of osteoporotic fracture, or a low bone mass (T-score <-2.5 SD) in the absence of documented pre-existing osteoporotic fracture.
⚠️ কোনো ওষুধ গ্রহণের আগে সর্বদা নিবন্ধিত চিকিৎসকের পরামর্শ নিন।
ফার্মাকোলজি
The pharmacodynamic action of ibandronic acid is inhibition of bone resorption. In vivo, ibandronic acid prevents experimentally induced bone destruction caused by cessation of gonadal function, retinoids, tumors or tumor extracts. In young (fast growing) rats, the endogenous bone resorption is also inhibited, leading to increased bone mass compared with untreated animals. Animal models confirm that ibandronic acid is a highly potent inhibitor of osteoclastic activity. In growing rats, there was no evidence of impaired mineralization even at doses greater than 5,000 times the dose required for osteoporosis treatment. The high potency and therapeutic margin of ibandronic acid allows for more flexible dosing regimens and intermittent treatment with long drug-free intervals at comparatively low doses.Ibandronic acid is a highly potent bisphosphonate belonging to the nitrogen-containing group of bisphosphonates, which act on bone tissue and specifically inhibit osteoclast activity, It does not interfere with osteoclast recruitment. The selective action of ibandronic acid on bone tissue is based on the high affinity of this compound for hydroxyapatite, which represents the mineral matrix of the bone. Ibandronic acid reduces bone resorption, with no direct effect on bone formation. In postmenopausal women, it reduces the elevated rate of bone turnover towards premenopausal levels, leading to a progressive net gain in bone mass. Daily or intermittent administration of ibandronic acid results in reduced bone resorption as reflected in reduced levels of serum and urinary biochemical markers of bone turnover, increased BMD and a decreased incidence of fractures.
Pregnancy & Breastfeeding
Pregnancy: Ibandronic Acid should not be used during pregnancy. Studies in which rats and rabbits were given daily oral doses found no evidence of a direct toxic or teratogenic effect on the fetus, and no adverse effects on development were seen in the F1 offspring of rats. However, reproductive toxicity studies in rats showed the effects typically associated with bisphosphonates as a class, including a reduced number of implantation sites, interference with natural delivery (dystocia), and an increase in visceral variations (renal pelvis ureter syndrome). No specific studies have been carried out for the monthly dosing regimen, and there is no clinical experience with Ibandronic Acid in pregnant women.
Nursing Mothers: Ibandronic Acid should not be used by nursing mothers during lactation. In lactating rats given ibandronic acid intravenously at 0.08 mg/kg/day, the highest concentration of the drug found in breast milk was 8.1 ng/ml, occurring within the first 2 hours after administration. By 24 hours, the concentration in milk and in plasma had become similar, at about 5% of the level measured at the 2 hour mark.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
ডোজ নির্দেশিকা
⚠️ শুধুমাত্র সরকারি উৎস থেকে নির্দেশিকা পরিসীমা। ব্যক্তিগতকৃত ডোজের জন্য আপনার ডাক্তারের পরামর্শ নিন।
পার্শ্বপ্রতিক্রিয়া ও পারস্পরিক ক্রিয়া
পার্শ্বপ্রতিক্রিয়া
No side-effect data recorded yet.